Indivior Pharmaceuticals, Inc. (INDV)

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Symbol: INDV
Exchange: Nasdaq
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market cap: $4.38B
52 week range: 22.56 - 42.81

Valuation

Share price: $35.91 (close of 2026-09-23)
P/E (TTM): 12.77x
Price to book: -21.05x
Price to free cash flow: -39.44x
Enterprise value: $4.67B
Book value per share: $-1.75

Price performance

Period	Change
1 day	+1.07%
5 days	+4.94%
1 month	-2.60%
3 months	-10.14%
6 months	+22.18%
Year to date	+0.08%
1 year	+54.85%
3 years	+61.10%
5 years	+139.40%
10 years	+68.59%
All time	+237.18%

Profitability and growth

Return on equity: -214.29%
Return on invested capital: 401.72%
Return on assets: 17.49%
Return on capital employed: 91.29%
Gross margin: 80.23%
Net margin: 16.95%
EBITDA margin: 21.95%
Revenue growth: 4.29%
Net income growth: 2900.00%
Free cash flow growth: -1428.57%

Cash flow and balance sheet

Free cash flow yield (TTM): -2.54%
Current ratio: 0.84x
Net debt to EBITDA: 0.66x

Latest reported year

Period end: 2025-12-31
Fiscal year: 2025
Revenue: $1.24B
Cost of revenue: $246.00M
Gross profit: $994.00M
EBITDA: $272.00M
Net income: $210.00M
Earnings per share: $1.68
Shares outstanding: 125.00M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-12-31	$1.24B	$994.00M	$210.00M	$1.68
2024-12-31	$1.19B	$957.00M	$7.00M	$0.05
2023-12-31	$1.09B	$919.00M	$-126.00M	$-0.92
2022-12-31	$901.00M	$749.00M	$-44.00M	$-0.32
2021-12-31	$791.00M	$664.00M	$205.00M	$1.41

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity	Return on capital
2025-12-31	80.23%	16.95%	-214.29%	401.72%
2024-12-31	80.56%	0.59%	-2.08%	-
2023-12-31	84.08%	-11.53%	0.00%	-
2022-12-31	83.13%	-4.88%	-86.27%	-
2021-12-31	83.94%	25.92%	100.99%	-